Lp-PLA2 is an emergent proatherogenic molecule, predicting cardiovascular disease and mortality in the general population as well as in cardiac or diabetic patients, so that the three major heart international societies, the American Heart Association, the American College of Cardiology and the European Society of Cardiology, include the Lp-PLA2 activity determination in the risk stratification charts in order to optimize the lipid lowering treatment [35]. The gene discussed is PLA2G7; the disease is cardiovascular disorder.